KASINGER JAMES R. 4

What Happened

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics (CRSP), had 5,500 derivative awards (restricted stock units) convert to common shares on March 10, 2026, and a portion of the resulting shares were sold. On March 11, 2026 he sold 2,800 shares in an open-market transaction at $52.80 per share for proceeds of $147,840. The conversion/vesting was from a March 10, 2023 RSU grant (22,000 shares total; quarterly vesting over four years).

Key Details

• Transaction dates and prices:
  • 2026-03-10: 5,500 shares converted from derivative/RSU (reported as an M-code exercise/conversion).
  • 2026-03-11: 2,800 shares sold at $52.80 each for $147,840 (open-market sale).
• Shares owned after transaction: Not specified in the excerpt of the filing provided.
• Footnotes / notable items:
  • The shares arose from RSUs granted 2023-03-10 with quarterly vesting (one quarter vested each year through 2027) (F4).
  • The 2,800-share sale represents the number of shares required to be sold to cover tax withholding on vesting per the company’s RSU Settlement Policy; it was a mandated sale, not a discretionary trade (F2, F3).
  • Some of the converted shares remain subject to a lock‑up agreement with underwriters related to the company’s convertible senior notes due 2031 (F1).
• Filing timeliness: Form 4 was filed on 2026-03-12 for transactions dated March 10–11, 2026; this appears to be a timely filing under normal Form 4 deadlines.

Context

• The March 10 entries reflect conversion/vesting of restricted stock units (derivative exercise/conversion). The subsequent sale on March 11 was to satisfy tax withholding obligations (a common, non-discretionary practice) rather than an opportunistic sell. This type of forced sale generally does not signal management’s market view.